Skip to main content
Log in

Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis

  • Original Paper
  • Published:
Pathology & Oncology Research

Abstract

Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is overexpressed in advanced stage prostate adenocarcinomas. As a novel target for in vivo prognostic and therapeutic approaches, the distribution pattern of PSMA in primary and metastatic tumors is of significant interest. In this study we addressed the cellular distribution and heterogeneity of PSMA expression. Paraffin-embedded sections of 51 patients with primary prostate carcinoma and distant metastases were evaluated. Immunohistochemistry was used to determine the cellular localization, staining intensity and positive cell fraction which were related to tumor type and growth pattern. We demonstrated differences in the intracellular localization of the PSMA immunostaining which seem to be related to the tumor differentiation pattern. A significant number of the primary tumors (7/51) and metastases (6/51) presented with highly heterogeneous PSMA expression and in further 2 primary, and 8 metastatic tumors the staining was in the negative range (<10% positive tumor cells). A direct correlation between histological parameters and PSMA expression could not be demonstrated. Our findings clearly support the feasibility but also direct to potential failures of PSMA-targeted in vivo diagnostic and therapeutic approaches in prostate cancer patients with distant metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

A:

Apical

AB:

Antibody

C:

Cytoplasmic

GM:

Gabor Mehes

IHC:

Immunohistochemistry

M:

Membrane

PSMA:

Prostate-Specific Membrane Antigen

PSA:

Prostate Specific Antigen

SD:

Standard Deviation

SM:

Sebastian Mannweiler

TUR:

Transurethrally Resected

References

  1. Chang SS (2004) Overview of prostate-specific membrane antigen. Rev Urol 6:S13–S16

    Article  PubMed  Google Scholar 

  2. Pinto JT, Suffoletto BP, Berzin TM et al (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2:1445–1451

    CAS  PubMed  Google Scholar 

  3. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82:2256–2261

    Article  CAS  PubMed  Google Scholar 

  4. Perner S, Hofer MD, Kim R, Shah RB, Li H, Möller P, Hautmann RE, Gschwendt JE, Kuefer R, Rubin MA (2007) Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol 38:696–701

    Article  CAS  PubMed  Google Scholar 

  5. Horoszewicz JS, Kawinski E, Murphy GP (1987) Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res 7:927–936

    CAS  PubMed  Google Scholar 

  6. Moreno JG, Croce CM, Fischer R et al (1992) Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 52:6110–6112

    CAS  PubMed  Google Scholar 

  7. Silver DA, Pellicer I, Fair WL et al (1997) Prostate-specific membrane antigen expression in normal and malignant human tissue. Clin Cancer Res 3:81–85

    CAS  PubMed  Google Scholar 

  8. Chang S, O’Keefe DS, Bacich DJ, Reuter VE, Heston WD Gaudin PB (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5:2674–2681

    CAS  PubMed  Google Scholar 

  9. Wright GL, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334

    Article  PubMed  Google Scholar 

  10. Gleason DF (1977) Histologic grading and clinical staging of prostatic carcinoma. In: Tannebaum M (ed) Urologic pathology: the prostate. Lea & Febiger, Philadelphia, pp 171–197

    Google Scholar 

  11. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R, Montironi R (2006) Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448(2):111–118

    Article  PubMed  Google Scholar 

  12. Douglas G. Altman: Practical Statistics for Medical Research Chapman & Hall/CRC 1 edition (November 22, 1990)

  13. Bander NH (2006) Technology insight: monoclonal antibody imaging of prostate cancer. Nat Clin Pract Urol 3(4):216–225

    Article  CAS  PubMed  Google Scholar 

  14. Sodee DB, Sodee AE, Bakale G (2007) Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin Nucl Med 37(1):17–28

    Article  PubMed  Google Scholar 

  15. Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U (2006) A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66(13):1359–1370

    Article  PubMed  Google Scholar 

  16. Ross JS, Sheehan CHE, Fisher HAG, Kaufman RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BVS (2003) Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 9:6357–6362

    CAS  PubMed  Google Scholar 

  17. Zhigang Z, Wenly S (2004) Prostate stem cell antigen (PSCA) expression in human prostate cancer tissue and its potential role in prostate carcinogenesis and progression of prostate cancer. W J Surg Oncol 2:1–13

    Article  Google Scholar 

  18. Bühler P, Wolf P, Gierschner D, Schabel I, Katzenwadel A, Schultze-Seemann W, Wetterauer U, Tacke M, Swamy M, Schamel WW, Elsässer-Beile U (2008) A bispecific diabody directed against prostate-specific membrane antigen and CD33 induces T-cell mediated lysis of prostate cancer cells. Can Immunol Immunother 57(1):43–52

    Article  Google Scholar 

Download references

Acknowledgments

The authors thank Elisabeth Patz and Anja Hausleitner for their excellent technical assistance and Harald Zöbl for the graphical layout and design.

Legal declaration

IRB approval formally obtained according to the votum 12-159 ex 01/02 at Medical University Graz, Austria.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Sebastian Mannweiler.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mannweiler, S., Amersdorfer, P., Trajanoski, S. et al. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis. Pathol. Oncol. Res. 15, 167–172 (2009). https://doi.org/10.1007/s12253-008-9104-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-008-9104-2

Keywords

Navigation